Cite
HARVARD Citation
Farnier, M. et al. (2016). Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. Atherosclerosis. pp. e254-. [Online].